United Health Products, Inc. announced that it has received the final report from an independent review of the results of its human clinical trial.
HENDERSON, Nev., Oct. 18, 2019 (GLOBE NEWSWIRE) -- United Health Products, Inc. (OTC: UEEC), (“UHP” or the “Company”), manufacturer and marketer of HemoStyp®, an Oxidized Regenerated Cellulose that is patented through Oct 2029 (US Patent 8,557,874 Oct 15, 2013), for the healthcare and wound care sectors, today announced that it has received the final report from an independent review of the results of its human clinical trial. The review confirmed the non-inferiority and superiority of HemoStyp over Surgicel, the market leader for hemostatic agents.
In summary the independent statistical reviewer (http://www.stat4ward.com/who_we_are) stated:
“For the primary analysis comparing HemoStyp versus Surgicel for hemostasis in 10 minutes, both non-inferiority and superiority were satisfied in both ITT population and PP population. For the secondary analysis, HemoStyp was significantly better than Surgicel with respect to the percentage achieving hemostasis at 2 minutes, 5 minutes, and 10 minutes.”
The website https://www.clinicaltrials.gov/ct2/show/NCT03654560?term=hemostyp&rank=1 is being updated with all relevant data and supporting documents and will be continuously updated over the next several weeks.
This trial was conducted on 236 WIRB (Western Institutional Review Board) approved and consented patients. Surgeries consisted of Level 1 and Level 2 bleeds on the Lewis bleeding scale for abdominal, cardiovascular, thoracic and vascular surgeries.
UHP is continuing its discussions with well positioned candidates interested in acquisition of the Company or partnerships that allow penetration into the surgical markets.
About United Health Products
United Health Products develops technology, manufactures and markets patented hemostatic products for the healthcare and wound care sectors. The product, HemoStyp, is derived from regenerated oxidized cellulose. HemoStyp is an all-natural product designed to control bleeding. UHP is focused on identifying new markets and applications for its products and expanding its current markets. UHP currently sells a suite of hemostatic products to the dental, veterinary and retail markets.
For more on United Health Products, Inc. visit: www.unitedhealthproductsinc.com
Safe Harbor Statement
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.
Company Contact:
United Health Products, Inc.
877-358-3444
IR Contact :
PAN Consultants Ltd.
Philippe Niemetz 212-344-6464 p.niemetz@panconsultants.com
